BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 25989432)

  • 1. Should patients with chronic liver disease receive venous thromboembolism prophylaxis?
    Dang JD; Davis LE
    JAAPA; 2015 Jun; 28(6):27-8, 30. PubMed ID: 25989432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of pharmacologic prophylaxis for venous thromboembolism in patients with chronic liver disease.
    Barclay SM; Jeffres MN; Nguyen K; Nguyen T
    Pharmacotherapy; 2013 Apr; 33(4):375-82. PubMed ID: 23553808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suboptimal use of pharmacological venous thromboembolism prophylaxis in cirrhotic patients.
    Yang LS; Alukaidey S; Croucher K; Dowling D
    Intern Med J; 2018 Sep; 48(9):1056-1063. PubMed ID: 29468795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of hemorrhage in patients with chronic liver disease and coagulopathy receiving pharmacologic venous thromboembolism prophylaxis.
    Reichert JA; Hlavinka PF; Stolzfus JC
    Pharmacotherapy; 2014 Oct; 34(10):1043-9. PubMed ID: 25052037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of High-Dose Unfractionated Heparin Versus High-Dose Enoxaparin for Venous Thromboembolism Prevention in Morbidly Obese Hospitalized Patients.
    Mason SW; Barber A; Jones E; Chen SL; Moll S; Northam K
    Am J Med; 2020 Jun; 133(6):e249-e259. PubMed ID: 31862336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic prophylaxis against venous thromboembolism in hospitalized patients with cirrhosis and associated coagulopathies.
    Koliscak L; Maynor L
    Am J Health Syst Pharm; 2012 Apr; 69(8):658-63. PubMed ID: 22472867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population.
    Reeves D; Liu CY
    J Oncol Pharm Pract; 2010 Mar; 16(1):27-31. PubMed ID: 19401307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of venous thromboembolism in patients with chronic liver disease and the utility of venous thromboembolism prophylaxis.
    Pincus KJ; Tata AL; Watson K
    Ann Pharmacother; 2012 Jun; 46(6):873-8. PubMed ID: 22570429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline.
    Lederle FA; Zylla D; MacDonald R; Wilt TJ
    Ann Intern Med; 2011 Nov; 155(9):602-15. PubMed ID: 22041949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Retrospective Cohort Analysis of Pharmacologic VTE Prophylaxis and Padua Prediction Score in Hospitalized Patients With Chronic Liver Disease.
    Moorehead KJ; Jeffres MN; Mueller SW
    J Pharm Pract; 2017 Feb; 30(1):58-63. PubMed ID: 26475125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venous thromboembolism in cancer patients.
    Deng A; Galanis T; Graham MG
    Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Summaries for patients: Preventing venous thromboembolism in hospitalized patients: recommendations from the American College of Physicians.
    Ann Intern Med; 2011 Nov; 155(9):I38. PubMed ID: 22041965
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and Effectiveness of Enoxaparin as Venous Thromboembolism Prophylaxis after Gastric Cancer Surgery in Japanese Patients.
    Yanagita T; Kusanagi H
    Am Surg; 2016 Dec; 82(12):1232-1237. PubMed ID: 28234190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Underutilization of anticoagulant for venous thromboembolism prophylaxis in three hospitals in Jakarta.
    Atmakusuma TD; Tambunan KL; Sukrisman L; Effendi S; Rachman A; Setiawati A; Rinaldi I; Mulansari NA; Rajabto W; Nasution SA; Muhadi ; Aninditha T; Sedono R; Sugiarto A; Pitoyo CW; Paramitha D; Astoro NW; Nasution IR
    Acta Med Indones; 2015 Apr; 47(2):136-45. PubMed ID: 26260556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overuse of venous thromboembolism prophylaxis among hospitalized patients with liver disease.
    Davis JPE; O'Leary KE; Intagliata NM
    Eur J Haematol; 2020 Mar; 104(3):223-229. PubMed ID: 31797441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the use of venous thromboembolism prophylaxis in an Australian teaching hospital.
    Gallagher M; Oliver K; Hurwitz M
    Qual Saf Health Care; 2009 Oct; 18(5):408-12. PubMed ID: 19812106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians.
    Qaseem A; Chou R; Humphrey LL; Starkey M; Shekelle P;
    Ann Intern Med; 2011 Nov; 155(9):625-32. PubMed ID: 22041951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors and safety of venous thromboembolism prophylaxis among hospitalized inflammatory bowel disease patients.
    Ra G; Thanabalan R; Ratneswaran S; Nguyen GC
    J Crohns Colitis; 2013 Nov; 7(10):e479-85. PubMed ID: 23537817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-molecular-weight heparin and mortality in acutely ill medical patients.
    Kakkar AK; Cimminiello C; Goldhaber SZ; Parakh R; Wang C; Bergmann JF;
    N Engl J Med; 2011 Dec; 365(26):2463-72. PubMed ID: 22204723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective review of the use of thromboprophylaxis in patients who subsequently developed a venous thromboembolism after discharge from hospital.
    Wiseman DN; Harrison J
    N Z Med J; 2010 Feb; 123(1309):37-49. PubMed ID: 20186241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.